Safety profile and clinical activity of multiple subcutaneous doses of MEDI-528 a humanized anti-interleukin-9 monoclonal antibody in two randomized phase 2a studies in subjects with asthma

摘要

BackgroundInterleukin-9 (IL-9)-targeted therapies may offer a novel approach for treating asthmatics. Two randomized placebo-controlled studies were conducted to assess the safety profile and potential efficacy of multiple subcutaneous doses of MEDI-528, a humanized anti-IL-9 monoclonal antibody, in asthmatics.